Tomorrow's world: Atherosclerosis in the year 2000

Netherlands Journal of Medicine

Volumn 50, Issue 5, 1997, Pages 221-227

  Shepherd, J ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Atherosclerosis; Dyslipidaemia; Lipid lowering therapy; Pravastatin; Risk assessment; Risk benefit

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; PLACEBO; PRAVASTATIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

ANTICHOLESTEREMIC AGENTS; CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; PROSPECTIVE STUDIES;

EID: 0030951043     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(97)00011-9     Document Type: Article

References (4)

1. West Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996;348:1339-1342.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholosterolemia. N Engl J Med 1995;333:1301-1307.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med I996;335:1001-1009.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.